JP2023526890A5 - - Google Patents
Info
- Publication number
- JP2023526890A5 JP2023526890A5 JP2022560455A JP2022560455A JP2023526890A5 JP 2023526890 A5 JP2023526890 A5 JP 2023526890A5 JP 2022560455 A JP2022560455 A JP 2022560455A JP 2022560455 A JP2022560455 A JP 2022560455A JP 2023526890 A5 JP2023526890 A5 JP 2023526890A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutical composition
- nos
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041014994 | 2020-04-04 | ||
| IN202041014994 | 2020-04-04 | ||
| CU2020000027A CU20200027A7 (es) | 2020-04-17 | 2020-04-17 | Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas |
| CUCU-2020-0027 | 2020-04-17 | ||
| PCT/IB2021/052793 WO2021199006A1 (en) | 2020-04-04 | 2021-04-03 | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526890A JP2023526890A (ja) | 2023-06-26 |
| JP2023526890A5 true JP2023526890A5 (cg-RX-API-DMAC7.html) | 2024-04-12 |
Family
ID=77928142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560455A Pending JP2023526890A (ja) | 2020-04-04 | 2021-04-03 | Covid-19を包含するコロナウイルスの負の効果を処置および低減をするための抗cd6抗体組成物および方法 |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2993186T (pt) | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| IL266087B2 (en) * | 2016-10-18 | 2024-02-01 | Biocon Ltd | Use of itolizumab to reduce phosphorylation of cd6 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| PT2993186T (pt) * | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| KR20110091780A (ko) * | 2008-11-25 | 2011-08-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 악액질, 쇠약, 피로 및/또는 발열을 예방하거나 치료하는 il6의 길항제 |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US10562975B2 (en) * | 2016-06-15 | 2020-02-18 | The Regents Of The University Of Michigan | CD6 antibody for treatment of T-cell mediated diseases or disorders |
| WO2019169015A1 (en) * | 2018-02-27 | 2019-09-06 | Equillium, Inc. | Anti cd6 antibodies for treating severe asthma |
| AU2020415307A1 (en) * | 2019-12-24 | 2022-06-09 | F. Hoffmann-La Roche Ag | Method of treating virus infection using a TLR7 agonist |
-
2021
- 2021-03-03 US US17/916,910 patent/US20230151107A1/en active Pending
- 2021-04-03 EP EP21781113.2A patent/EP4126961A4/en active Pending
- 2021-04-03 JP JP2022560455A patent/JP2023526890A/ja active Pending
- 2021-04-03 KR KR1020227038692A patent/KR20220165267A/ko active Pending
- 2021-04-03 CA CA3174566A patent/CA3174566A1/en active Pending
- 2021-04-03 MX MX2022012229A patent/MX2022012229A/es unknown
- 2021-04-03 AU AU2021247258A patent/AU2021247258A1/en not_active Abandoned
- 2021-04-03 CN CN202180039042.4A patent/CN115698071A/zh active Pending
- 2021-04-03 BR BR112022018936A patent/BR112022018936A2/pt not_active IP Right Cessation
- 2021-04-03 WO PCT/IB2021/052793 patent/WO2021199006A1/en not_active Ceased
- 2021-04-03 IL IL296487A patent/IL296487A/en unknown
- 2021-04-06 TW TW110112416A patent/TW202200202A/zh unknown
-
2022
- 2022-09-08 ZA ZA2022/10032A patent/ZA202210032B/en unknown
- 2022-09-30 CL CL2022002684A patent/CL2022002684A1/es unknown
- 2022-10-04 CO CONC2022/0014199A patent/CO2022014199A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6811723B2 (ja) | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 | |
| Gulati et al. | Cytokines and their role in health and disease: a brief overview | |
| KR100912381B1 (ko) | 응고 관련 질병을 치료하기 위한 조성물 및 방법 | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| US6846486B1 (en) | Method of treating allergy by administering an anti-histamine antibody | |
| KR20070090969A (ko) | 톨 유사 수용체 3 길항제, 방법 및 용도 | |
| RU2009136677A (ru) | Рекомбинантные антитела для лечения респираторно-синцитиальных вирусных инфекций | |
| JP2017113019A5 (cg-RX-API-DMAC7.html) | ||
| JP2005533861A5 (cg-RX-API-DMAC7.html) | ||
| JP2005523946A5 (cg-RX-API-DMAC7.html) | ||
| US20090117105A1 (en) | Humanized anti-venezuelan equine encephalitis virus recombinant antibody | |
| JPH04211392A (ja) | モノクローナル抗体、抗体特性を有する蛋白質、ハイブリドーマ細胞系及びモノクローナル抗体の作製法 | |
| CN115515976A (zh) | 冠状病毒抗体 | |
| JP2017515473A5 (cg-RX-API-DMAC7.html) | ||
| KR20180088442A (ko) | 병원내 폐렴의 예방 또는 치료 방법 | |
| CN117603358B (zh) | 一种广谱新型冠状病毒的双特异性抗体 | |
| JP2008545381A5 (cg-RX-API-DMAC7.html) | ||
| AU2010264764A1 (en) | Pharmaceutical agent | |
| CA2729226C (en) | Pharmaceutical compositions of antibodies for diseases caused by viruses | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体 | |
| JP2022513438A5 (cg-RX-API-DMAC7.html) | ||
| WO2023122786A3 (en) | ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19 | |
| JP6800591B2 (ja) | インフルエンザ治療剤 | |
| KR101453516B1 (ko) | 항-vegf 항체를 포함하는 자가면역질환 예방 및 치료용 조성물 |